Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.75 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.61 |
| ▸ | TUBB | P07437 | 1/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.61 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.61 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.61 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497353 | 1.00 | NFE2L2 (0.75) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL1603723 | 0.86 | NFE2L2 (1.00) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL5500710 | 0.86 | NFE2L2 (1.00) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL3937908 | 0.85 | NFE2L2 (0.56) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL27882842 | 0.85 | NFE2L2 (0.64) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL27651551 | 0.85 | NFE2L2 (0.64) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 | |
| SCHEMBL9190919 | 0.84 | CYP19A1 (0.73) | NFE2L2CYP19A1CYP1A1CYP1B1TUBB1 | |
| SCHEMBL5494173 | 0.84 | CYP19A1 (0.73) | NFE2L2CYP19A1CYP1A1CYP1B1TUBB1 | |
| SCHEMBL5494166 | 0.84 | CYP19A1 (0.73) | NFE2L2CYP19A1CYP1A1CYP1B1TUBB1 | |
| SCHEMBL29136488 | 0.84 | TUBB1 (0.69) | NFE2L2CYP19A1CYP1A1CYP1B1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229216-B1 | DETECTION AND ANALYSIS OF STRUCTURAL VARIATIONS IN GENOMES | UNIV LELAND STANFORD JUNIOR (US) | 2026-04-22 | — | — | EP | claimed |
| US-20250346951-A1 | METHODS FOR AMPLIFYING POLYNUCLEOTIDE SEQUENCES IN SITU | Singular Genomics Systems, Inc. | 2025-11-13 | — | — | US | claimed |
| US-12391988-B2 | Sequencing a target sequence in a cell | Singular Genomics Systems, Inc. (US) | 2025-08-19 | — | — | US | claimed |
| US-20250115958-A1 | METHODS FOR DETECTING POLYNUCLEOTIDE SEQUENCES IN SITU | FIRST-CITIZENS BANK & TRUST COMPANY | 2025-04-10 | — | — | US | claimed |
| US-12091660-B2 | Detection and analysis of structural variations in genomes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-09-17 | — | — | US | claimed |
| EP-4427758-A1 | NEW SYNERGISTIC ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIBACTERIAL ASSOCIATION | NOOS S.r.l. (IT) | 2024-09-11 | — | — | EP | claimed |
| US-20240271208-A1 | METHODS FOR DIFFERENTIATING MODIFIED NUCLEOBASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | claimed |
| EP-4396339-A1 | METHODS FOR DIFFERENTIATING MODIFIED NUCLEOBASES | Singular Genomics Systems, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| US-20240158845-A1 | METHODS AND COMPOSITIONS FOR SEQUENCING COMPLEMENTARY POLYNUCLEOTIDES | Singular Genomics Systems, Inc. | 2024-05-16 | — | — | US | claimed |
| US-11913071-B2 | Methods and compositions for sequencing complementary polynucleotides | Singular Genomics Systems, Inc. (US) | 2024-02-27 | — | — | US | claimed |
| EP-2060255-A2 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | The Regents Of The University Of California (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2009035539-A2 | LONG INTERFERING NUCLEIC ACID DUPLEXES TARGETING MULTIPLE RNA TARGETS | NT OMICS INC. (US) | 2009-03-19 | — | — | WO | claimed |
| EP-1450819-A4 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | UNIV CALIFORNIA (US) | 2008-01-23 | — | — | EP | claimed |
| CN-101026959-A | Fungicidally active polymer dispersions and use thereof | CELANESE EMULSIONS GMBH (DE) | 2007-08-29 | — | — | CN | claimed |
| EP-1796459-A2 | FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF | Celanese Emulsions GmbH (DE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006034762-A2 | FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF | CELANESE EMULSIONS GMBH (DE) | 2006-04-06 | — | — | WO | claimed |
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-02 | — | — | US | claimed |
| EP-1450819-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | The Regents of the University of California (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003039557-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003031381-A2 | SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF | UNIVERSITE LOUIS PASTEUR (FR) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | TNF, HLA-DRB1, IL5 | NFE2L2 730/4885CYP19A1 427/4885CYP1A1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.